Months after the U.S. Food and Drug Administration (FDA) rejected Insys Therapeutics’ buprenorphine sublingual spray for moderate-to-severe acute pain, the Arizona-based company is assessing strategic alternatives for its opioid-related assets as it continues to shift its focus to a new therapeutic – cannabinoids.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,